Eduardo Bruno Martins - 18 Jul 2023 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Chief Medical Officer
Signature
/s/ Dennis Hom, Attorney-in-Fact
Issuer symbol
SGMT
Transactions as of
18 Jul 2023
Net transactions value
$0
Form type
4
Filing time
20 Jul 2023, 16:17:28 UTC
Previous filing
13 Jul 2023
Next filing
21 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMT Stock Option (Right to Buy) Disposed to Issuer $0 -198,132 -100% $0.000000* 0 18 Jul 2023 Common Stock 198,132 $6.36 Direct F1, F2
transaction SGMT Stock Option (Right to Buy) Award $0 +198,132 $0.000000 198,132 18 Jul 2023 Series A Common Stock 198,132 $6.36 Direct F1, F2
transaction SGMT Stock Option (Right to Buy) Disposed to Issuer $0 -44,009 -100% $0.000000* 0 18 Jul 2023 Common Stock 44,009 $13.51 Direct F1, F3
transaction SGMT Stock Option (Right to Buy) Award $0 +44,009 $0.000000 44,009 18 Jul 2023 Series A Common Stock 44,009 $13.51 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2 25% of the shares underlying this option vested and became exercisable on February 16, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3 The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 20, 2023, subject to the Reporting Person's continued service on each such vesting date.